| 2025-02-28 | +117.0% | news | Seeking Alpha | BioXcel Therapeutics regains compliance with Nasdaq |
| 2025-08-04 | +115.8% | news | StocksToTrade | BioXcel Therapeutics Stock Unveiled: Rollercoaster Insights - StocksToTrade |
| 2025-08-04 | +115.8% | news | timothysykes.com | BioXcel Therapeutics Surges: What’s Behind the Move? - timothysykes.com |
| 2025-08-01 | +94.0% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-08-11 | +67.5% | legal | SEC EDGAR | BTAI 8-K: 8.01 and (SEC Filing) |
| 2023-06-29 | -63.9% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2024-02-08 | -44.8% | legal | SEC EDGAR | BTAI 8-K: 8.01 and (SEC Filing) |
| 2024-02-08 | -44.8% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-02-06 | -44.2% | news | Seeking Alpha | BioXcel to execute 1-for-16 reverse stock split |
| 2025-02-06 | -44.2% | news | Yahoo Finance | BioXcel Therapeutics Announces Reverse Stock Split - Yahoo Finance |
| 2025-02-06 | -44.2% | news | Stock Titan | BioXcel's Strategic Reverse Split: Critical Move to Preserve Nasdaq Status - What's at Stake - Stock Titan |
| 2023-08-14 | -43.4% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2023-08-14 | -43.4% | news | The Motley Fool | Why BioXcel Therapeutics Stock Is Getting Crushed Today - The Motley Fool |
| 2022-11-10 | +32.2% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2023-10-25 | +30.8% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-08-13 | -30.5% | news | Yahoo Finance | BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - Yahoo Finance |
| 2025-08-13 | -30.5% | earnings | simplywall.st | BioXcel Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st |
| 2025-08-13 | -30.5% | analyst | StocksToTrade | Mizuho Cuts Price Target for BioXcel Amid Neutral Stance - StocksToTrade |
| 2025-03-03 | +27.9% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-03-04 | -27.1% | legal | SEC EDGAR | BTAI 8-K: 1.01 and (SEC Filing) |
| 2025-08-26 | -23.9% | news | Stocktwits | All Eyes On BioXcel Stock As Phase 3 Data For Bipolar, Schizophrenia Drug Due Today - Stocktwits |
| 2023-03-09 | -23.9% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2025-08-27 | -22.3% | news | Seeking Alpha | BioXcel whipsaws after late-stage trial win for lead asset |
| 2025-08-27 | -22.3% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-08-27 | -22.3% | news | Seeking Alpha | BioXcel stock down despite late-stage trial win (BTAI:NASDAQ) - Seeking Alpha |
| 2025-08-27 | -22.3% | earnings | Yahoo Finance | UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® - Yahoo Finance |
| 2025-08-27 | -22.3% | news | StocksToTrade | Should BioXcel Be On Your Radar? - StocksToTrade |
| 2023-11-14 | -22.3% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2024-11-13 | -21.2% | earnings | Seeking Alpha | BioXcel Therapeutics Q3 2024 Earnings Preview |
| 2025-08-07 | +21.0% | news | Upstox | BioXcel Therapeutics, Inc. Share Price Today - Live NASDAQ: BTAI Stock Price Charts, History - Upstox |
| 2025-08-07 | +21.0% | legal | StocksToTrade | Best Biotech Stocks to Watch in August 2025: From AI Testing to FDA Fast Trackers - StocksToTrade |
| 2024-08-09 | -20.2% | news | Investing.com | BTAI stock plunges to 52-week low of $0.73 amid market challenges - Investing.com |
| 2025-08-15 | +19.6% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-11-12 | -18.7% | earnings | Seeking Alpha | BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84 |
| 2025-11-12 | -18.7% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2025-11-12 | -18.7% | earnings | Quiver Quantitative | BIOXCEL THERAPEUTICS Earnings Results: $BTAI Reports Quarterly Earnings - Quiver Quantitative |
| 2025-11-12 | -18.7% | earnings | Yahoo Finance | BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance |
| 2025-11-12 | -18.7% | earnings | TradingView | BioXcel Therapeutics Q3 2025 Financial Results and Clinical Program Updates - TradingView |
| 2025-01-08 | -18.6% | legal | SEC EDGAR | BTAI 8-K: 5.02 and (SEC Filing) |
| 2024-11-22 | -18.3% | news | Seeking Alpha | BioXcel Therapeutics announces pricing of $7M public offering |
| 2023-05-08 | +18.1% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2024-02-12 | +18.0% | legal | SEC EDGAR | BTAI 8-K: 1.01 and (SEC Filing) |
| 2025-12-01 | -16.6% | news | StocksToTrade | Top Biotech Penny Stocks to Watch Out for in 2025 - StocksToTrade |
| 2021-10-13 | -16.2% | legal | SEC EDGAR | BTAI 8-K: 5.02 (SEC Filing) |
| 2022-11-30 | +15.3% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-01-07 | +15.3% | news | Stock Titan | Drugmaker moves to bring at-home relief for bipolar agitation - Stock Titan |
| 2026-01-07 | +15.3% | legal | GlobeNewswire | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® - GlobeNewswire |
| 2026-03-16 | +14.8% | executive | Stock Titan | BioXcel Therapeutics (BTAI) CEO Vimal Mehta exercises RSUs for 383 shares - Stock Titan |
| 2024-11-21 | -14.3% | news | Seeking Alpha | BioXcel announces common stock and warrants offering, no amount given |
| 2024-11-21 | -14.3% | legal | SEC EDGAR | BTAI 8-K: 1.01, 3.02, 5.02, 8.01 (SEC Filing) |
| 2022-04-07 | -14.2% | legal | SEC EDGAR | BTAI 8-K: 1.01 and 8.01 (SEC Filing) |
| 2025-08-06 | +14.1% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-08-06 | +14.1% | news | Quiver Quantitative | BioXcel Therapeutics Stock (BTAI) Opinions on Phase 3 SERENITY Trial Completion - Quiver Quantitative |
| 2025-08-12 | -13.9% | earnings | Seeking Alpha | BioXcel Therapeutics GAAP EPS of -$2.45 misses by $0.59, revenue of $0.12M misses by $0.09M |
| 2025-08-12 | -13.9% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2025-08-12 | -13.9% | earnings | Yahoo Finance | BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance |
| 2025-08-12 | -13.9% | legal | Yahoo Finance | BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - Yahoo Finance |
| 2025-08-12 | -13.9% | news | StocksToTrade | BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments - StocksToTrade |
| 2025-08-12 | -13.9% | legal | TradingView | BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - TradingView |
| 2026-04-01 | -12.8% | news | GlobeNewswire | BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting |
| 2026-04-01 | -12.8% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-04-01 | -12.8% | legal | Stock Titan | BioXcel Therapeutics (BTAI) gets FDA review date for IGALMI at-home agitation use - Stock Titan |
| 2026-04-01 | -12.8% | legal | Stock Titan | BioXcel seeks first at-home FDA-approved agitation treatment - Stock Titan |
| 2026-04-01 | -12.8% | news | GlobeNewswire | BioXcel Therapeutics Announces Food & Drug Administration - GlobeNewswire |
| 2026-04-01 | -12.8% | legal | Investing.com | FDA accepts BioXcel Therapeutics application for IGALMI in at-home agitation treatment - Investing.com |
| 2025-02-21 | -12.2% | news | Investing.com | BTAI stock plunges to 52-week low of $2.16 amid market challenges - Investing.com |
| 2026-02-06 | +12.2% | legal | SEC EDGAR | BTAI 8-K: 5.02 and (SEC Filing) |
| 2026-02-06 | +12.2% | news | Investing.com | BioXcel Therapeutics announces milestone and retention bonuses for key executives - Investing.com |
| 2022-07-06 | +12.0% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2022-08-09 | -11.4% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2026-04-17 | +11.1% | news | Insider Monkey | H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns |
| 2026-04-17 | +11.1% | expansion | GlobeNewswire | BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting |
| 2026-04-17 | +11.1% | legal | SEC EDGAR | BTAI 8-K: 3.02 and (SEC Filing) |
| 2026-04-17 | +11.1% | news | Stock Titan | BioXcel Therapeutics (NASDAQ: BTAI) grants 1,353,729 low-price warrants - Stock Titan |
| 2026-04-17 | +11.1% | news | Stock Titan | 86M annual at-home agitation episodes shape BioXcel's IGALMI plan - Stock Titan |
| 2026-04-17 | +11.1% | news | Yahoo Finance | H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns - Yahoo Finance |
| 2023-03-10 | -11.0% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-05-27 | -10.8% | news | Seeking Alpha | BioXcel Therapeutics gets extension from Nasdaq to regain compliance |
| 2025-05-27 | -10.8% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2024-09-19 | -10.6% | news | Seeking Alpha | BioXcel ends commercial support for Igalmi as focus turns to neuro candidate |
| 2024-09-19 | -10.6% | legal | SEC EDGAR | BTAI 8-K: 2.05 and 5.02 (SEC Filing) |
| 2022-07-05 | +10.5% | legal | SEC EDGAR | BTAI 8-K: 5.02 (SEC Filing) |
| 2025-05-12 | -10.5% | earnings | Seeking Alpha | BioXcel Therapeutics GAAP EPS of -$1.50 beats by $1.54, revenue of $0.17M misses by $0.18M |
| 2025-05-12 | -10.5% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2024-06-25 | +10.4% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-08-19 | -10.3% | news | Yahoo Finance | BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - Yahoo Finance |
| 2025-08-19 | -10.3% | news | Finimize | BioXcel Jumps On Speculation Of A Big Biotech Breakthrough - Finimize |
| 2024-08-10 | -10.0% | earnings | Seeking Alpha | BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript |
| 2024-11-25 | -9.7% | legal | SEC EDGAR | BTAI 8-K: 1.01 and (SEC Filing) |
| 2025-08-18 | -9.7% | legal | SEC EDGAR | BTAI 8-K: 8.01 and (SEC Filing) |
| 2025-08-18 | -9.7% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-08-18 | -9.7% | news | Investing.com | BioXcel Therapeutics files prospectus supplement for $80 million ATM program - Investing.com |
| 2025-08-18 | -9.7% | news | StocksToTrade | Growth or Bubble? Examining BioXcel’s Surge - StocksToTrade |
| 2026-03-27 | -9.6% | news | GlobeNewswire | BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting |
| 2026-03-27 | -9.6% | earnings | Seeking Alpha | BioXcel Therapeutics GAAP EPS of -$0.58 beats by $0.06, revenue of $0.26M beats by $0.11M |
| 2026-03-27 | -9.6% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2023-02-21 | -9.4% | legal | SEC EDGAR | BTAI 8-K: 8.01 and (SEC Filing) |
| 2022-07-21 | -9.4% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2024-12-17 | -9.2% | news | Investing.com | Bioxcel therapeutics exec sells $58 in stock - Investing.com |
| 2026-03-10 | -9.0% | news | GlobeNewswire | BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - GlobeNewswire |
| 2026-03-10 | -9.0% | news | Investing.com | BioXcel Therapeutics raises $8M in registered direct offering - Investing.com |
| 2024-04-10 | +8.8% | legal | SEC EDGAR | BTAI 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-11-10 | +8.6% | legal | SEC EDGAR | BTAI 8-K: 8.01 and (SEC Filing) |
| 2024-10-15 | +8.6% | news | Seeking Alpha | BioXcel announces defense grant to UNC to fund study for treating acute stress disorder |
| 2026-03-05 | -8.4% | news | Stock Titan | Drug film BXCL501 eases opioid withdrawal in Columbia University study - Stock Titan |
| 2026-03-05 | -8.4% | news | GuruFocus | BioXcel Therapeutics (BTAI) Target Price Lowered by HC Wainwrigh - GuruFocus |
| 2026-03-05 | -8.4% | news | StocksToTrade | BioXcel Therapeutics Stock Soars Amid New Drug Approval Speculation - StocksToTrade |
| 2026-03-05 | -8.4% | news | timothysykes.com | BioXcel Therapeutics Achieves Milestone with Igalmi’s Market Study - timothysykes.com |
| 2026-03-05 | -8.4% | news | timothysykes.com | BioXcel Therapeutics Seeks Market Expansion amid Financial Struggles - timothysykes.com |
| 2026-03-05 | -8.4% | news | Asianet Newsable | Why Did BTAI Stock Surge 20% In Pre-Market Today? - Asianet Newsable |
| 2026-03-17 | +8.3% | analyst | Investing.com | BioXcel Therapeutics stock initiated with buy rating at Rodman - Investing.com |
| 2026-03-17 | +8.3% | analyst | GuruFocus | BTAI: BioXcel Therapeutics Initiates Coverage with 'Buy' Rating - GuruFocus |
| 2026-03-17 | +8.3% | analyst | Benzinga | This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga |
| 2025-05-13 | -8.2% | news | Intellectia AI | BTAI Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2026-04-23 | -8.2% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | BTAI BioXcel Therapeutics Inc. gains 7.48 percent after posting narrower than expected Q4 2025 EPS results. - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | -8.2% | earnings | Xã Thanh Hà | BTAI (BioXcel Therapeutics Inc.) reports narrower Q4 2025 loss than expected, shares gain 7.48 percent on upbeat investor reaction. - NCAV - Xã Thanh Hà |
| 2025-12-04 | +8.1% | analyst | Yahoo Finance | What Analysts Think Is Changing The Story For BioXcel Therapeutics Now - Yahoo Finance |
| 2026-01-15 | -7.7% | news | Business Wire | Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire |
| 2024-10-09 | -7.7% | legal | SEC EDGAR | BTAI 8-K: 5.02 and (SEC Filing) |
| 2022-05-09 | -7.6% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2025-04-03 | -7.6% | legal | SEC EDGAR | BTAI 8-K: 1.01 and (SEC Filing) |
| 2025-12-11 | -7.4% | news | Seeking Alpha | BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript |
| 2026-04-02 | -7.1% | analyst | Investing.com | H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com |
| 2024-09-05 | -7.1% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-02-27 | -7.0% | news | Seeking Alpha | BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript |
| 2025-05-30 | +6.9% | news | Intellectia AI | BTAI Forecast — Price Prediction for 2026. Should I Buy BTAI? - Intellectia AI |
| 2023-09-07 | +6.7% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2022-03-10 | -6.6% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2025-09-10 | -6.4% | news | Seeking Alpha | BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) |
| 2025-09-10 | -6.4% | news | Seeking Alpha | BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call - Slideshow |
| 2025-09-10 | -6.4% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2024-11-14 | -6.3% | earnings | Seeking Alpha | BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript |
| 2024-11-14 | -6.3% | earnings | Seeking Alpha | BioXcel Therapeutics GAAP EPS of -$0.32 beats by $0.23, revenue of $0.21M misses by $1.12M |
| 2024-11-14 | -6.3% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2023-12-06 | -6.0% | legal | SEC EDGAR | BTAI 8-K: 1.01, 1.02, 2.03, 3.02 (SEC Filing) |
| 2026-01-21 | -5.9% | legal | The Globe and Mail | BioXcel seeks FDA approval for at-home IGALMI use - The Globe and Mail |
| 2024-04-22 | +5.9% | legal | SEC EDGAR | BTAI 8-K: 7.01, 8.01 (SEC Filing) |
| 2022-09-12 | -5.9% | legal | SEC EDGAR | BTAI 8-K: 8.01 and (SEC Filing) |
| 2023-05-17 | -5.9% | analyst | TradingView | BTAI Forecast — Price Target — Prediction for 2027 - TradingView |
| 2023-04-20 | +5.7% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2024-07-16 | +5.7% | earnings | Seeking Alpha | BioXcel Therapeutics expects 141% Y/Y revenue surge for Q2 |
| 2024-07-16 | +5.7% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2025-07-21 | -5.7% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2023-03-15 | -5.5% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2024-07-17 | -5.3% | legal | SEC EDGAR | BTAI 8-K: 1.01 (SEC Filing) |
| 2025-04-25 | +5.2% | news | Stock Titan | BTAI Stock Price, News & Analysis - Stock Titan |
| 2026-01-17 | +4.8% | news | Yahoo Finance | 1 Top Penny Stock to Watch Now - Yahoo Finance |
| 2024-05-11 | +4.5% | earnings | MarketBeat | BioXcel Therapeutics (BTAI) Stock Forecast and Price Target 2026 $BTAI - MarketBeat |
| 2025-03-21 | -4.5% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2021-12-02 | +4.4% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-09-15 | -4.3% | legal | SEC EDGAR | BTAI 8-K: 7.01 and 8.01 (SEC Filing) |
| 2025-09-04 | +4.2% | news | Yahoo Finance | BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Yahoo Finance |
| 2026-04-09 | -4.1% | news | PR Newswire | Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire |
| 2023-09-25 | -4.1% | legal | SEC EDGAR | BTAI 8-K: 1.01, 5.02 (SEC Filing) |
| 2026-04-08 | -4.1% | news | GlobeNewswire | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions |
| 2026-04-08 | -4.1% | news | Stock Titan | BioXcel drug enters U.S. military-funded study for acute stress after trauma - Stock Titan |
| 2023-12-18 | -4.0% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-04-04 | -3.9% | news | Intellectia AI | BTAI Technical Analysis & Stock Price Forecast - Intellectia AI |
| 2022-04-19 | -3.8% | legal | SEC EDGAR | BTAI 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2026-03-30 | +3.8% | news | Stock Titan | Qatar Investment Authority (BTAI) reports 156,066 BioXcel shares owned - Stock Titan |
| 2026-03-29 | -3.6% | news | Simply Wall St. | How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks |
| 2026-03-29 | -3.6% | news | Yahoo Finance | How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks - Yahoo Finance |
| 2025-07-15 | -3.4% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2023-09-19 | -3.3% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2023-09-12 | -3.3% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-03-12 | -3.0% | news | Simply Wall St. | How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs |
| 2026-03-12 | -3.0% | news | Yahoo Finance | How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs - Yahoo Finance |
| 2026-03-12 | -3.0% | news | The Globe and Mail | BioXcel Therapeutics Announces Registered Direct Equity Financing - The Globe and Mail |
| 2023-02-13 | -3.0% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-03-31 | -2.9% | legal | Stock Titan | BTAI SEC Filings - Bioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2022-09-20 | -2.8% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for BioXcel Therapeutics (BTAI) - Zacks Investment Research |
| 2024-09-09 | -2.7% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2024-05-08 | -2.5% | earnings | Seeking Alpha | BioXcel Therapeutics Q1 2024 Earnings Preview |
| 2025-09-18 | +2.4% | news | Seeking Alpha | BioXcel regains compliance with Nasdaq listing rule |
| 2026-02-13 | +2.4% | news | Stock Titan | BTAI Financials: Income Statement, Balance Sheet & Cash Flow | Bioxcel Therapeutics Inc - Stock Titan |
| 2025-10-14 | +2.4% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-10-14 | +2.4% | news | Nasdaq | BioXcel Therapeutics Rings the Closing Bell - Nasdaq |
| 2025-10-14 | +2.4% | news | Yahoo Finance | BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes - Yahoo Finance |
| 2024-03-25 | +2.2% | legal | SEC EDGAR | BTAI 8-K: 1.01 and (SEC Filing) |
| 2026-04-13 | -2.2% | news | Simply Wall St. | How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks |
| 2026-04-13 | -2.2% | news | Yahoo Finance | How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance |
| 2025-03-05 | +2.2% | news | Hartford Business Journal | BioXcel Therapeutics raises $14M in direct offering - Hartford Business Journal |
| 2024-05-09 | -2.1% | earnings | Seeking Alpha | BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript |
| 2024-05-09 | -2.1% | earnings | Seeking Alpha | BioXcel Therapeutics GAAP EPS of -$0.87 misses by $0.12, revenue of $0.58M misses by $0.05M |
| 2024-05-09 | -2.1% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | +2.0% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-01-12 | +2.0% | news | Stock Titan | Drugmaker taps veteran to pursue at-home treatment for bipolar agitation - Stock Titan |
| 2024-03-12 | -2.0% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2023-08-15 | -1.8% | news | Yahoo Finance | Further weakness as BioXcel Therapeutics (NASDAQ:BTAI) drops 42% this week, taking three-year losses to 90% - Yahoo Finance |
| 2025-10-13 | +1.7% | news | Yahoo Finance | BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation - Yahoo Finance |
| 2025-01-16 | -1.7% | legal | SEC EDGAR | BTAI 8-K: 5.02 (SEC Filing) |
| 2021-11-10 | -1.6% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2026-03-11 | +1.6% | news | MT Newswires | BioXcel Therapeutics Closes $8.0 Million Direct Offering |
| 2026-03-11 | +1.6% | news | GlobeNewswire | BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering |
| 2026-03-11 | +1.6% | legal | SEC EDGAR | BTAI 8-K: 1.01 and (SEC Filing) |
| 2026-03-11 | +1.6% | news | Stock Titan | AI-driven drugmaker BioXcel raises $8M, extends investor warrants - Stock Titan |
| 2026-03-11 | +1.6% | news | Investing.com | BioXcel Therapeutics closes $8M registered direct offering - Investing.com |
| 2026-03-11 | +1.6% | news | The Manila Times | BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - The Manila Times |
| 2025-07-09 | -1.4% | earnings | MarketBeat | BioXcel Therapeutics (BTAI) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BTAI - MarketBeat |
| 2024-08-06 | -1.2% | earnings | Seeking Alpha | BioXcel Therapeutics GAAP EPS of -$0.21 beats by $0.57, revenue of $1.1M in-line |
| 2024-08-06 | -1.2% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2024-12-23 | +1.2% | analyst | Yahoo Finance | BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance |
| 2025-07-11 | +1.2% | analyst | Yahoo Finance | BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress - Yahoo Finance |
| 2023-03-16 | -1.1% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-02-19 | -1.1% | news | Stock Titan | Doctors tackle 100M Alzheimer’s agitation episodes in new BioXcel webcast - Stock Titan |
| 2024-08-05 | -1.0% | earnings | Seeking Alpha | BioXcel Therapeutics Q2 2024 Earnings Preview |
| 2026-02-12 | -1.0% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-02-12 | -1.0% | news | Stock Titan | 86M at-home agitation episodes a year: IGALMI as potential option - Stock Titan |
| 2026-01-20 | +0.9% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-01-20 | +0.9% | legal | Stock Titan | At-home relief for agitation: FDA review sought for IGALMI film - Stock Titan |
| 2026-01-20 | +0.9% | news | Investing.com | BioXcel Therapeutics submits sNDA for at-home use of IGALMI - Investing.com |
| 2023-12-12 | +0.9% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2022-08-19 | +0.9% | legal | SEC EDGAR | BTAI 8-K: 5.02 and (SEC Filing) |
| 2025-01-10 | +0.9% | news | Seeking Alpha | BioXcel Therapeutics files to sell 5.1M shares of common stock by selling shareholders |
| 2023-08-22 | +0.7% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2025-03-27 | -0.5% | earnings | Seeking Alpha | BioXcel Therapeutics GAAP EPS of -$3.57 beats by $3.37, revenue of $0.37M misses by $0.35M |
| 2025-03-27 | -0.5% | legal | SEC EDGAR | BTAI 8-K: 2.02 and (SEC Filing) |
| 2022-01-13 | -0.3% | legal | SEC EDGAR | BTAI 8-K: 2.02 and 7.01 (SEC Filing) |
| 2025-10-30 | -0.2% | legal | SEC EDGAR | BTAI 8-K: 8.01 (SEC Filing) |
| 2026-02-14 | -0.2% | news | Intellectia AI | BTAI Should I Buy - Intellectia AI |
| 2025-02-07 | -0.2% | news | Hartford Business Journal | BioXcel Therapeutics announces reverse stock split - Hartford Business Journal |
| 2025-12-21 | -0.0% | news | Trefis | Is BioXcel Therapeutics Stock Built to Withstand More Downside? - Trefis |
| 2026-04-24 | — | expansion | Seeking Alpha | BioXcel Therapeutics, Inc. (BTAI) Discusses Commercial Launch Strategy and Market Opportunity for IGALMI in At-Home Setting Transcript |
| 2026-04-24 | — | analyst | ChartMill | BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill |